The effect of smoking on biological change of recurrent breast cancer
Authors:
- Koji TakadaKTKoji Takada
- Shinichiro KashiwagiShinichiro Kashiwagi
- Yuka AsanoYAYuka Asano
- Wataru GotoWGWataru Goto
- Rika KouhashiRKRika Kouhashi
- Akimichi YabumotoAYAkimichi Yabumoto
- Tamami MorisakiTMTamami Morisaki
- Hisakazu FujitaHFHisakazu Fujita
- Masatsune ShibutaniMSMasatsune Shibutani
- Tsutomu TakashimaTTTsutomu Takashima
- Kosei HirakawaKHKosei Hirakawa
- Masaichi OhiraMOMasaichi Ohira
Open Access
- 5 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-12
Abstract
Background: The selection of treatment for a patient with breast cancer largely relies on the cancer subtype. However, this process is complicated by changes in tumor biology at relapse. Smoking has been identified as a risk factor for breast cancer. The direct effect of a tobacco component delivered via blood circulation on the mammary gland tissue and subsequent DNA damage have been proposed to explain the association between cigarette smoking and breast cancer carcinogenesis. This postulation is supported by both tissue culture and animal studies demonstrating that the associated DNA damage further alters breast cancer cells, as indicated by an increased proliferative capacity and malignant transformation. In this study, we aimed to explore the relationship between changes in Estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) each receptor at recurrence, and smoking and the prognosis after recurrence. Methods: This retrospective study included 989 patients with primary breast cancer who developed relapse after surgery and 50 patients who underwent regenerative biopsy or surgery from December 2007 to March 2018. ER, PgR, and HER2 expression in the primary and recurrent lesions was evaluated using immunohistochemistry, and the correlations of these expression patterns with smoking history (pack-years) were examined. Results: When ER was evaluated in recurrent tumors, negative and positive conversions were recognized in 3 (6.0%) and 1 patient (2.0%), respectively. When PgR was evaluated, negative conversion was recognized in 15 patients (30.0%). When HER2 was evaluated, positive conversion was recognized in 6 patients (12.0%). Consequently, we observed a change in the intrinsic subtype in in 5 patients with recurrent tumors (10.0%). Although most clinical factors were not correlated with smoking, a positive conversion of HER2 in recurrence was significantly more frequent among smokers than among non-smokers (p = 0.024). Conclusions: Biological changes during breast cancer recurrence should be given careful clinical consideration because they affect treatment after recurrence. Our results suggest that smoking may induce increased HER2 expression in recurrent breast tumors.Keywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (19K18067, 26461957, 17K10559)
This publication has 34 references indexed in Scilit:
- Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysisAnnals of Oncology, 2012
- Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2012
- Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breastHistopathology, 2012
- Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growthBreast Cancer Research, 2011
- Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosisWorld Journal of Surgical Oncology, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)Breast Cancer Research, 2010
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals of Oncology, 2009
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Smoking associated with hormone receptor negative breast cancerInternational Journal of Cancer, 2001